Overview

A Study on the Safety and Effectiveness of Tislelizumab Combined With Axitinib for Neoadjuvant Treatment of ccRCC

Status:
Active, not recruiting

Trial end date:
2024-10-01

Target enrollment:

Participant gender:

Summary

This trial is a single-center clinical trial to evaluate the tumor shrinkage and safety of tislelizumab combined with axitinib in Neoadjuvant therapy of T2-T3N0M0 renal clear cell carcinoma

Phase:

Phase 2

Details

Lead Sponsor:

Hongqian Guo

Treatments:

Axitinib